$CARSGEN-B(02171)$ is propelling forward with a dual-engine strategy of “technological breakthroughs + commercial innovation” in the CAR-T space. As Saiceliz's sales network expands and CT041 embarks on a new journey in solid tumor treatment, the company’s RMB 1.479 billion cash reserve provides a solid foundation for global expansion.

For us, CARsgen’s leadership in the global cell therapy market, strong R&D capabilities, and accelerating commercialization process position it for long-term growth. With increasing product sales and more innovative therapies entering clinical stages, the company is poised for rapid performance breakthroughs, making its stock an attractive investment opportunity with promising upside potential.